WASHINGTON, D.C., July 8, 2026 – Baker Botts L.L.P., a leading international energy, technology, and life sciences law firm, represented UnitedHealth Group (NYSE: UNH) in the antitrust review of Optum Financial's acquisition of Alegeus Technologies.

Optum Financial, the financial services business within UnitedHealth Group's Optum subsidiary, closed the acquisition July 2, 2026. Alegeus provides benefits administration for consumer-directed healthcare accounts, including health savings accounts, flexible spending accounts, health reimbursement arrangements, and COBRA continuation coverage.

Baker Botts guided UnitedHealth Group through the Hart-Scott-Rodino filing and review process before the Department of Justice and Federal Trade Commission, allowing the deal to close.

Baker Botts has advised UnitedHealth Group on significant antitrust matters, including its $3.3 billion acquisition of Amedisys. That matter earned Merger Control Matter of the Year – Americas at the Global Competition Review Awards 2026.

The firm's Antitrust and Competition Law Practice Group advises clients on merger reviews, government investigations, litigation, and counseling. The team has more than 50 lawyers in Washington, D.C., Brussels, and London and represents clients before the DOJ, the FTC, the European Commission, the UK Competition and Markets Authority, and other competition authorities.

Baker Botts Lawyers/Offices Involved:

Antitrust: Jeffrey Oliver (Partner, Washington, D.C.); Anthony Swisher (Partner, Washington, D.C.); Michael Bodosky (Special Counsel, Washington, D.C.); Iain McPhie (Special Counsel, Washington, D.C.); Sarah Zhang (Senior Associate, Washington, D.C.); Rachel Rasp (Senior Associate, Washington, D.C.)